Oral platelet glycoprotein IIb/IIIa receptor antagonists: The present challenge is safety

Circulation

Volumn 97, Issue 4, 1998, Pages 312-314

  Vorchheimer, D A ^a   Fuster, V ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Drugs; Editorials; Glycoproteins; Platelet aggregation inhibitors; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; SIBRAFIBAN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0032477682     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.4.312     Document Type: Editorial

References (26)